Rocket Pharmaceuticals

Rocket Pharmaceuticals company information, Employees & Contact Information

Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company seeking gene therapy cures. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for our mission and making a difference for patients. Become an integral part of an agile, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. In addition to a competitive compensation package featuring a generous 401K match and stock options, positions include excellent health benefits. For more information, please visit www.rocketpharma.com. Twitter: https://bit.ly/2O28aHx YouTube: https://bit.ly/3iNSXIu
Looking for a particular Rocket Pharmaceuticals employee's phone or email?

Rocket Pharmaceuticals Questions

News

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - FinancialContent

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences FinancialContent

Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102 - CGTLive®

Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102 CGTLive®

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease - Business Wire

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Business Wire

Rocket Pharma: 2 Gene Therapy Candidates Anticipating Near-Term Review (NASDAQ:RCKT) - Seeking Alpha

Rocket Pharma: 2 Gene Therapy Candidates Anticipating Near-Term Review (NASDAQ:RCKT) Seeking Alpha

Rocket Snags IND Clearance for BAG3-DCM Gene Therapy Trial - CGTLive®

Rocket Snags IND Clearance for BAG3-DCM Gene Therapy Trial CGTLive®

Rocket’s PKP2-Arrhythmogenic Cardiomyopathy Gene Therapy RP-A601 Improves or Stabilizes Heart Function in Phase 1 Trial - CGTLive®

Rocket’s PKP2-Arrhythmogenic Cardiomyopathy Gene Therapy RP-A601 Improves or Stabilizes Heart Function in Phase 1 Trial CGTLive®

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Business Wire

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy Business Wire

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference Business Wire

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress Business Wire

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease - Business Wire

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease Business Wire

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy - Business Wire

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy Business Wire

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - Business Wire

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress Business Wire

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease - Business Wire

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease Business Wire

AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans | Circulation: Genomic and Precision Medicine - American Heart Association Journals

AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans | Circulation: Genomic and Precision Medicine American Heart Association Journals

Rocket Pharmaceuticals Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors - citybiz

Rocket Pharmaceuticals Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors citybiz

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors - citybiz

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors citybiz

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Stock Titan

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock Stock Titan

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy - Business Wire

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy Business Wire

Rocket Pharmaceuticals Appoints Jessie Yeung as VP of Investor Relations and Corporate Finance - citybiz

Rocket Pharmaceuticals Appoints Jessie Yeung as VP of Investor Relations and Corporate Finance citybiz

Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference - FinancialContent

Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference FinancialContent

Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference - FinancialContent

Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference FinancialContent

Top Rocket Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant